欧洲实验室对血脂异常管理指南的依从性:CAMARGUE研究
CAMARGUE研究由EFLM发起,2019年通过问卷调查欧洲28国452家临床实验室的血脂检测实践。结果显示66%实验室始终使用非空腹血样,59%以mmol/L报告血脂谱,仅不足半数采用指南推荐LDL胆固醇阈值标记,17%在疑似家族性高胆固醇血症时添加警示注释,23%在高甘油三酯血症胰腺炎风险高时添加注释。结论认为欧洲实验室在分析前、分析中和分析后血脂管理存在显著差异,可能对临床产生重要影响。
要点
- 66%的欧洲实验室始终使用非空腹血样进行血脂检测。
- 仅不足半数实验室采用指南推荐的LDL胆固醇阈值进行标记。
- 仅17%实验室在疑似家族性高胆固醇血症时添加警示注释。
核心结论
- 欧洲实验室在血脂分析前、分析和分析后管理方面存在显著差异,可能对临床产生重要影响。
研究设计与样本
- 2019年通过EFLM国家学会向欧洲临床实验室分发网络问卷,覆盖分析前、分析方法、测量单位、决策阈值标记及决策增强注释使用。
- 共获得来自28个国家的452家实验室回复。
主要发现
- 66%的实验室始终使用非空腹血样进行血脂检测。
- 59%的实验室以mmol/L报告血脂谱,主要来自14个推广SI单位的国家。
- 决策阈值标记存在重要差异,不足半数实验室采用指南推荐的LDL胆固醇阈值。
- 仅17%的实验室在疑似家族性高胆固醇血症时添加警示注释。
- 23%的实验室在高甘油三酯血症胰腺炎风险高时添加警示注释。
临床怎么用
- 实验室应关注血脂检测分析前、分析和分析后全流程的指南依从性。
- 应重视决策阈值标记和决策增强注释的规范使用,以支持临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CArdiac MARker Guidelines Uptake in Europe Study (CAMARGUE) initiated by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) aims to survey the current use of evidence-based guidelines for dyslipidemia testing in Europe. METHODS: In 2019 a web-based questionnaire was distributed via EFLM National Societies to clinical laboratories in Europe. Questions covered pre-analytics, analytical methods, measurement units, flagging of decision thresholds, and use of decision-enhancing comments. RESULTS: Returns were obtained from 452 laboratories from 28 countries. Most laboratories always use nonfasting blood samples for lipid assays (66%). Lipid profiles are reported in mmol/L by 59% of the laboratories, mainly from 14 countries promoting the use of SI units. Important differences in flagging of decision thresholds were observed, with less than half of the laboratories applying the guideline-recommended LDL cholesterol threshold. Only 17% of the laboratories add an alert comment when familial hypercholesterolemia is suspected and 23% when risk of pancreatitis from hypertriglyceridemia is high. CONCLUSIONS: There are marked differences among laboratories in Europe in terms of pre-analytical, analytical, and post-analytical lipid management that could have an important clinical impact. This relates to different availability of assays or different laboratory practices on reporting and flagging of lipid profiles.
引用
- De Wolf HA, Langlois MR, Suvisaari J, et al. How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) study. Clin Chim Acta. 2020. PMID: 32454048. doi:10.1016/j.cca.2020.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。